Therox – BIBA Medtech Insights

CE mark for SuperSaturated oxygen therapy

TherOX DS2 ZOLL Medical has received CE Mark approval to market and distribute its SuperSaturated oxygen (SSO2) therapy system in Europe. A press release reports that SSO2 therapy provides interventional cardiologists with the first and only clinically proven treatment beyond percutaneous coronary intervention (PCI) to significantly reduce muscle damage in myocardial infarction [...]

FDA approve TherOx system for reducing heart damage in “widowmaker” myocardial infarction patients

TherOX DS2 Zoll has received FDA approval of the second-generation TherOx system, which—a press release reports—provides super-saturated oxygen (SSO2) therapy. SSO2 therapy is designed to deliver hyperbaric levels of oxygen directly to the damaged heart muscle immediately after successful revascularisation via angioplasty and stenting of the blocked coronary artery. The press release [...]